[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=118982b27e9581ee65be0e24caa7af73c6b7589361fbc9a9339fbb4222b831df",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747326600,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 134491292,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=118982b27e9581ee65be0e24caa7af73c6b7589361fbc9a9339fbb4222b831df"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies not seeing significant impact to Merck, Bristol from draft guidance",
    "summary": "Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single source qualifying drugs. The updated language on single source qualifying fixed dose combo products in the draft makes it seem as if subcutaneous Keytruda/Opdivo will be eligible for negotiation in 2028, but “We’re not sure this is true,” says the analyst, who is not seeing a significant impact to Merck",
    "url": "https://finnhub.io/api/news?id=a5e23610b27ea36bddd804267019ff16d2b16141897332c37609c40a079c1a32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747320402,
      "headline": "Jefferies not seeing significant impact to Merck, Bristol from draft guidance",
      "id": 134483656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single source qualifying drugs. The updated language on single source qualifying fixed dose combo products in the draft makes it seem as if subcutaneous Keytruda/Opdivo will be eligible for negotiation in 2028, but “We’re not sure this is true,” says the analyst, who is not seeing a significant impact to Merck",
      "url": "https://finnhub.io/api/news?id=a5e23610b27ea36bddd804267019ff16d2b16141897332c37609c40a079c1a32"
    }
  },
  {
    "ts": null,
    "headline": "What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks",
    "summary": "The Trump Administration recently signed an executive order that calls for most-favored-nation prices on brand-name drugs.  Branded drug prices in the U.S. can be several times higher than prices negotiated abroad.  This isn't the first time a Trump Administration attempted to implement a most-favored-nation drug pricing program.",
    "url": "https://finnhub.io/api/news?id=28456d3431b9e00d54595e3047c9f67bc81a51a5703b56cd46ebec3418dee546",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747303020,
      "headline": "What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks",
      "id": 134465777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Trump Administration recently signed an executive order that calls for most-favored-nation prices on brand-name drugs.  Branded drug prices in the U.S. can be several times higher than prices negotiated abroad.  This isn't the first time a Trump Administration attempted to implement a most-favored-nation drug pricing program.",
      "url": "https://finnhub.io/api/news?id=28456d3431b9e00d54595e3047c9f67bc81a51a5703b56cd46ebec3418dee546"
    }
  }
]